Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) vs TB-PPD for Tuberculosis Infection Diagnosis
CTR20230337Phase 4Completed
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in Tuberculosis (TB), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Feb 2023; status: completed.
02
Drugs
icotinib
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on CTR20230337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230337.